







eisha hylton-Rodic ene A. Lang nomis Namenga-Combs lyssa K. Sandrowstz nashan M. Stang han P. Weerakoon hand P. Weerakoon washan M. Bezos nuce B. Vance sish I. Sher goon L. Pickard dile K. D. Napoll chard B. Almon hilton P. Laude Bliss P. Laude Blissa P. Laude agisteend Patent Amentsnen B. Markwakez Gaurav Asthana Tasser Mourtada Julie L. Bilm. Cymilia L. Defenzio Rajah W. Powers Erin C. Wong Joseph E. Mutschelknaus Karon Nasabzadeh Aaron S. Ward Of Counsel Edward J. Kessler Kenneth C. Bass III Christocher P. Wist David C. Isascon

. . .

Federal Agencies

WRITER'S DIRECT NUMBER:
(202) 772-8582

Art Unit 1611

Attn: Mail Stop AF

INTERNET ADDRESS: PJACKMAN@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/502,403; § 371(c) Date: June 20, 2005

For: Pharmaceutical Composition to Control Blood Glucose in Patients with Type 2 Diabetes

Inventor: José Manuel Francisco LARA OCHOA

Our Ref: 2099.0090000/PAJ/UWJ

Sir

Transmitted herewith for appropriate action are the following documents:

Amendment and Reply Under 37 C.F.R. § 1.116 along with Exhibits A and B.

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman Attorney for Applicant Registration No. 45,986

PAJ/LMB/pcd Encls.

962705\_1.DOC